What is Corvus Pharmaceuticals?
Headquartered in Burlingame, California, Corvus Pharmaceuticals is a clinical-stage biopharmaceutical entity dedicated to the discovery and commercialization of novel oncology treatments. The company operates at the intersection of advanced immunology and targeted therapy, focusing on medicines that address the unmet needs of patients suffering from difficult-to-treat malignancies. By leveraging a deep understanding of cancer biology, Corvus aims to transform the standard of care through precision medicine, maintaining a rigorous focus on clinical execution and scientific excellence within the competitive global healthcare market.
How much funding has Corvus Pharmaceuticals raised?
Corvus Pharmaceuticals has raised a total of $244.3M across 4 funding rounds:
Series A
$33.5M
Series B
$75M
Stock Offering
$71M
Stock Offering
$64.8M
Series A (2014): $33.5M with participation from OrbiMed
Series B (2015): $75M led by Blackrock, Novo Ventures, Roche, Cowen, Cormorant Asset Management, Fidelity Management and Research Company, venBio Select, Sphera Funds Management, OrbiMed, T. Rowe Price, Jennison Associates, Adams Street Partners, and Rock Springs Capital
Stock Issuance/Offering (2016): $71M supported by Credit Suisse and Cowen & Co.
Stock Issuance/Offering (2018): $64.8M featuring Credit Suisse and Jefferies Financial Group
Key Investors in Corvus Pharmaceuticals
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics with deep expertise in life sciences innovation.
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in life science companies.
Fidelity Management and Research Company
Fidelity Investments is a global financial services firm providing comprehensive investment, wealth management, and advisory solutions to institutional and individual clients.
What's next for Corvus Pharmaceuticals?
Looking ahead, Corvus Pharmaceuticals is poised to leverage its recent capital influx to advance its clinical pipeline and strengthen its market position. The strategic deployment of these funds will likely prioritize the expansion of ongoing clinical trials and the optimization of its therapeutic platforms. As the company continues to navigate the complexities of drug development, the focus remains on achieving key clinical milestones that validate its scientific approach. With a solid balance sheet and continued support from institutional partners, Corvus is well-positioned to pursue long-term value creation, potentially exploring further strategic collaborations or licensing opportunities to enhance its commercial reach and therapeutic impact in the oncology sector.
See full Corvus Pharmaceuticals company page
